ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
23 hedge funds and large institutions have $13.5M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 2 closing their positions.
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
108% more capital invested
Capital invested by funds: $6.49M → $13.5M (+$7.01M)
21% more funds holding
Funds holding: 19 → 23 (+4)
5.54% more ownership
Funds ownership: 15.59% → 21.13% (+5.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$2.2M |
| 2 |
Jane Street
New York
|
+$1.42M |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$612K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$274K |
| 5 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$250K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
BCWM LLC
Overland Park,
Kansas
|
-$100K |
| 2 |
Citigroup
New York
|
-$24K |
| 3 |
APA
American Portfolios Advisors
Holbrook,
New York
|
-$2.04K |
| 4 |
CA
Calton & Associates
Tampa,
Florida
|
-$1K |
CNCR Hedge Fund Activity: Q1 2018 in Review
23 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q1 2018, worth a combined $13.5M — up 108% from $6.49M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CNCR positions and 2 closed out — a net gain of 4 holders — while 9 added to existing stakes and 2 trimmed.
The largest buyer was LPL Financial, adding an estimated $2.2M. The largest seller was BCWM LLC, cutting an estimated $100K.
- 23 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q1 2018, up from 19 in Q4 2017.
- Funds reported $13.5M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q1 2018, up 108% quarter-over-quarter.
- 6 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q1 2018 and 2 closed out, a net change of +4 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q1 2018 was LPL Financial, an estimated $2.2M added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q1 2018 was BCWM LLC, an estimated $100K sold.
Based on aggregated 13F filings for Q1 2018.